Skip to main content

Blum Robert I's Form 4 filing

Cytokinetics IncCYTK · filed Nov 18, 2026

Accession no.
0001061983-26-000116
Filed
Nov 18, 2026, 7:12 PM ET
Trade date
Nov 16, 2026
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $401.5K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Blum Robert ICIK 0001288859Director, Officer (President & CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 16, 2026Common StockMOption exerciseAcquired+7,500$10.60+$79,500286,044Direct
Nov 16, 2026Common StockSSaleDisposed−5,077$53.22F1−$270,197.94280,967Direct
Nov 16, 2026Common StockSSaleDisposed−2,223$54.08F2−$120,219.84278,744Direct
Nov 16, 2026Common StockSSaleDisposed−200$55.21F3−$11,042278,544Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 16, 2026Common StockMOption exerciseDisposed−7,500$0.00$0126,745Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The reported transaction involves sale transactions from $52.80 to $53.80 per share. The weighted average price per share was $53.22. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price

Referenced by the price of 1 transaction in Table I.

F2

The reported transaction involves sale transactions from $53.80 to $54.46 per share. The weighted average price per share was $54.08. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price

Referenced by the price of 1 transaction in Table I.

F3

The reported transaction involves sale transactions from $54.94 to $55.59 per share. The weighted average price per share was $55.21. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)